N-(4-羟基-2-甲氧基苯基)乙酰胺 | 5307-06-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: N-(4-羟基-2-甲氧基苯基)乙酰胺
• 英文名称: N-(4-hydroxy-2-methoxyphenyl)acetamide
• CAS: 5307-06-2
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: WSLZRANFLVSYSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-羟基-2-甲氧基苯基)乙酰胺 在 盐酸 、 alkaline solution 作用下， 生成 2,4-二甲氧基苯胺
  参考文献：
  名称：

  Heidelberger; Jacobs, Journal of the American Chemical Society, 1919, vol. 41, p. 1457

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙酰氨基苯甲醚 在 三氟乙酸 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 氯仿 为溶剂， 反应 0.05h， 以72%的产率得到N-(4-羟基-2-甲氧基苯基)乙酰胺
  参考文献：
  名称：

  使用苯基碘（III）双（三氟乙酸）酯在对位引入羟基和N-芳酰胺的N-碘苯基化。

  摘要：

  描述了在三氟乙酸（TFA），TFA-CHCl3或六氟异丙醇（HFIP）中，苯甲酸酯与苯基碘（III）双（三氟乙酸酯）（PIFA）的反应。当苯胺的酰基具有高负电性时，例如三氟乙酰基，或者苯基被吸电子基团取代，则4-碘苯基从PIFA转移到酰胺氮上，得到乙酰基二芳基胺。另一方面，当酰基具有诸如4-甲氧基苯基之类的供电子功能时，或者苯基被供电子性基团取代时，三氟乙酰氧基被转移至苯胺芳环的对位。该组在后处理过程中水解产生相应的苯酚。

  DOI：

  10.1021/jo0260847

文献信息

• Dey et al., Journal Of Scientific and Industrial Research, 1951, vol. 10 B, p. 175,178
  作者：Dey et al.

  DOI：——

  日期：——
• SEPSIS PROGNOSIS BIOMARKERS
  申请人：Langley Raymond

  公开号：US20150024969A1

  公开（公告）日：2015-01-22

  A method for determining prognosis, diagnosis and theronosis of a sepsis infection in a patient is disclosed. The method involves measuring the age, mean arterial pressure, hematocrit, patient temperature, and the concentration of one or more metabolites that are predictive of sepsis severity. The method can involve obtaining a blood sample from said patient and determining the concentration of the metabolite in the patient's blood; and then determining the severity of sepsis infection by analyzing the measured values in a weighted logistic regression equation.
• Biomarkers for Bladder Cancer and Methods Using the Same
  申请人：METABOLON, INC.

  公开号：US20150065366A1

  公开（公告）日：2015-03-05

  Methods for identifying and evaluating biochemical entities useful as biomarkers for bladder cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for bladder cancer.
• PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170276669A1

  公开（公告）日：2017-09-28

  The present invention relates to the field of nephrology. More specifically, the present invention provides methods and compositions useful for more precisely estimating glomerular filtration rate (GFR). In a specific embodiment, a method for calculating the estimated glomerular filtration rate (eGFR) in a patient comprises the steps of (a) measuring the level of one or more metabolites using mass spectrometry from a blood sample obtained from the patient; and (b) calculating the eGFR using an algorithm that utilizes the measured levels of the one or more metabolites.
• [EN] SEPSIS PROGNOSIS BIOMARKERS<br/>[FR] BIOMARQUEURS DE PRONOSTIC DE LA SEPTICÉMIE
  申请人：LANGLEY RAYMOND

  公开号：WO2013040099A2

  公开（公告）日：2013-03-21

  The present invention provides biomarkers and methods that may be used for sepsis prognosis, diagnosis and theronosis in a subject. A method for determining prognosis, diagnosis and theronosis of a sepsis infection in a patient is disclosed that can involve measuring the age, mean arterial pressure, hematocrit, patient temperature, and the concentration of one or more metabolites that are predictive of sepsis severity. The method can involve obtaining a blood sample from said patient and determining the concentration of the metabolite in the patient's blood; and then determining the severity of sepsis infection by analyzing the measured values in a weighted logistic regression equation. Not all of the markers need be assessed in every method only a sufficient number of markers to reliably determine the severity of the disease. Thus, a plurality of indicators can be measured which are selected from the group that includes a patient's age, mean arterial pressure, hematocrit, patient temperature, and the concentration of a metabolite selected from the group of metabolite markers consisting of 2-methylbutyrylcarnitine, 4-cis-decenoylcarnitine, butyrylcarnitine, hexanoylcarnitine, 4-methyl-2-oxopentanoate, 1- arachidonoylglycerophosphocholine, 1-linoleoylglycerophosphocholine, 3-(4- hydroxyphenyl)lactate (HPLA), 3-methoxytyrosine, n-acetylthreonine, pseudouridine and lactate and their combinations.